Hospital
ST. Mary's Medical Center, INC
ST. Mary's Medical Center, INC was paid $61.49M by Medicaid between Jan 2018 and Dec 2024, across 294 billing codes. Its largest line is 90999, dialysis (unlisted procedure) — 22% of everything it billed.
33Billing provider infoST. MARY'S MEDICAL CENTER, INC
WEST PALM BEACH, FL 33407
WEST PALM BEACH, FL 33407
33aNPI1952333205assigned 07/07/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$61.49M
24GClaims938,871
24DCodes billed294
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#2 of 163
Median peer was paid$4.77M
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 69,227 | $6.80M | |
| 2019 | 213,143 | $13.13M | |
| 2020 | 157,449 | $10.22M | |
| 2021 | 190,135 | $9.58M | |
| 2022 | 168,599 | $12.99M | |
| 2023 | 95,372 | $5.85M | |
| 2024incomplete | 44,946 | $2.92M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 90999 | Dialysis (unlisted procedure)Unlisted dialysis procedure, inpatient or outpatient | 22% | 33,932 | 2,580 | $13.59M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 67,014 | 61,915 | $6.97M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.8% | 50,589 | 43,698 | $5.38M |
| J1270 | Injection, doxercalciferol, 1 mcg | 8.1% | 14,362 | 1,462 | $4.95M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.6% | 18,060 | 15,812 | $2.82M |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | 3.1% | 5,231 | 1,590 | $1.88M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 13,910 | 13,088 | $1.72M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 17,171 | 3,356 | $1.72M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 7,532 | 6,558 | $1.50M |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 2.1% | 3,989 | 1,051 | $1.31M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.0% | 18,924 | 4,420 | $1.23M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 2,526 | 2,312 | $1.11M |
282 more codes
| 80053 | Comprehensive metabolic panel | 1.7% | 30,367 | $1.07M |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 1.7% | 3,095 | $1.06M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 14,707 | $931K |
| 84100 | 1.2% | 3,658 | $734K | |
| 85027 | 1.2% | 7,815 | $716K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 1.2% | 4,589 | $708K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 12,488 | $689K |
| 85018 | 1.1% | 2,323 | $661K | |
| 81001 | 1.1% | 36,185 | $646K | |
| 59025 | Fetal non-stress test | <1% | 9,145 | $475K |
| G0378 | Hospital observation service, per hour | <1% | 14,753 | $464K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,001 | $418K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 17,367 | $413K |
| 83970 | <1% | 1,514 | $412K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 20,947 | $404K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,764 | $335K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,048 | $329K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,566 | $314K |
| 87070 | <1% | 10,488 | $273K | |
| 54161 | <1% | 736 | $269K | |
| 82728 | <1% | 1,324 | $258K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,818 | $257K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 552 | $245K |
| 83540 | <1% | 903 | $235K | |
| 83550 | <1% | 877 | $235K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,174 | $235K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,317 | $211K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,187 | $177K |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,957 | $176K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,293 | $162K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,635 | $152K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,072 | $130K |
| 86803 | <1% | 380 | $122K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,897 | $119K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,227 | $115K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 664 | $111K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,955 | $110K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,772 | $106K |
| J3490 | Unclassified drugs | <1% | 880 | $101K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 560 | $93K |
| 81025 | <1% | 14,258 | $86K | |
| 86706 | <1% | 198 | $77K | |
| 76770 | <1% | 1,270 | $74K | |
| 74018 | <1% | 2,353 | $72K | |
| J0606 | Injection, etelcalcetide, 0.1 mg | <1% | 118 | $71K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,434 | $68K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,022 | $65K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 193 | $63K |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 675 | $62K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 8,466 | $62K |
| 36430 | <1% | 519 | $58K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,797 | $58K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,436 | $58K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,410 | $53K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 487 | $52K |
| 82570 | <1% | 1,786 | $50K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,086 | $50K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,506 | $50K |
| S5010 | 5% dextrose and 0.45% normal saline, 1000 ml | <1% | 559 | $48K |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | <1% | 416 | $43K |
| 82962 | <1% | 7,275 | $43K | |
| 92523 | <1% | 921 | $42K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,362 | $42K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,726 | $42K |
| 87631 | <1% | 587 | $41K | |
| 97163 | <1% | 394 | $41K | |
| 74019 | <1% | 1,986 | $37K | |
| 12011 | <1% | 615 | $36K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,804 | $32K |
| 70486 | <1% | 620 | $30K | |
| 76801 | <1% | 2,470 | $30K | |
| 87340 | <1% | 323 | $29K | |
| J1815 | Injection, insulin, per 5 units | <1% | 523 | $27K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 13,478 | $27K |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 339 | $25K |
| 74022 | <1% | 1,009 | $24K | |
| 84702 | <1% | 5,140 | $24K | |
| 90686 | <1% | 93 | $24K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 7,170 | $23K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,957 | $21K |
| 72128 | <1% | 46 | $20K | |
| 72131 | <1% | 256 | $19K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 503 | $19K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 917 | $18K |
| A9270 | Non-covered item or service | <1% | 3,357 | $17K |
| G0008 | Administration of influenza virus vaccine | <1% | 81 | $17K |
| 92567 | <1% | 829 | $17K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,342 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,956 | $15K |
| 12001 | <1% | 351 | $15K | |
| 87632 | <1% | 2,090 | $14K | |
| 96376 | <1% | 3,646 | $14K | |
| 92587 | <1% | 1,011 | $14K | |
| 87040 | <1% | 5,499 | $14K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,446 | $13K |
| 87205 | <1% | 2,248 | $13K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 639 | $13K |
| 77072 | <1% | 290 | $13K | |
| 73630 | <1% | 801 | $13K | |
| 86850 | <1% | 6,230 | $12K | |
| 82731 | <1% | 842 | $12K | |
| 92526 | <1% | 360 | $11K | |
| 73562 | <1% | 795 | $11K | |
| 85610 | <1% | 6,191 | $11K | |
| 80069 | <1% | 620 | $11K | |
| 76830 | Ultrasound, transvaginal | <1% | 497 | $11K |
| 73610 | <1% | 765 | $11K | |
| 86900 | <1% | 6,516 | $11K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 153 | $11K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 415 | $10K |
| 76536 | <1% | 167 | $10K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 649 | $9K |
| 86901 | <1% | 7,012 | $9K | |
| 76885 | <1% | 126 | $9K | |
| 93971 | <1% | 489 | $9K | |
| 82247 | <1% | 1,193 | $9K | |
| 74455 | <1% | 117 | $9K | |
| 93970 | <1% | 274 | $9K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 459 | $9K |
| 73130 | <1% | 687 | $8K | |
| 73090 | <1% | 485 | $8K | |
| 97168 | <1% | 84 | $8K | |
| 73590 | <1% | 458 | $8K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,340 | $8K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,236 | $8K |
| 97167 | <1% | 89 | $7K | |
| 97162 | <1% | 304 | $7K | |
| 84484 | <1% | 5,234 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,637 | $7K |
| 72100 | <1% | 676 | $7K | |
| 72170 | <1% | 450 | $7K | |
| 73030 | <1% | 761 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,022 | $6K |
| 92585 | <1% | 129 | $6K | |
| 01922 | <1% | 413 | $6K | |
| 73110 | <1% | 309 | $6K | |
| 85730 | <1% | 4,666 | $6K | |
| 76870 | <1% | 166 | $5K | |
| 97164 | <1% | 64 | $5K | |
| 72040 | <1% | 152 | $5K | |
| 94664 | <1% | 1,976 | $5K | |
| 83690 | <1% | 7,104 | $5K | |
| 87186 | <1% | 2,227 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,540 | $4K |
| 87045 | <1% | 274 | $4K | |
| 87077 | <1% | 2,212 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,718 | $4K |
| 93886 | <1% | 40 | $4K | |
| 84439 | <1% | 1,452 | $4K | |
| 10060 | <1% | 67 | $4K | |
| 86920 | <1% | 612 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,564 | $3K |
| 82270 | <1% | 91 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,695 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,670 | $3K |
| 96450 | <1% | 14 | $3K | |
| 84112 | <1% | 269 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,348 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,985 | $3K |
| 82550 | <1% | 3,210 | $3K | |
| 83735 | <1% | 4,672 | $3K | |
| 80061 | Lipid panel | <1% | 482 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 85 | $3K |
| 92579 | <1% | 51 | $2K | |
| 73140 | <1% | 39 | $2K | |
| 43762 | <1% | 12 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,444 | $2K |
| 82248 | <1% | 1,670 | $2K | |
| 83605 | <1% | 2,124 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,421 | $2K |
| 80076 | <1% | 544 | $2K | |
| 36416 | <1% | 381 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 119 | $2K |
| 73620 | <1% | 66 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,789 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,715 | $2K |
| 84703 | <1% | 732 | $1K | |
| 87210 | <1% | 1,952 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 295 | $1K |
| 12002 | <1% | 65 | $1K | |
| 73080 | <1% | 178 | $1K | |
| 92557 | <1% | 25 | $1K | |
| 76506 | <1% | 16 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,584 | $1K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 429 | $1K |
| 86140 | <1% | 7,781 | $1K | |
| 99001 | <1% | 4,723 | $1K | |
| 85046 | <1% | 1,213 | $1K | |
| 83880 | <1% | 1,283 | $1K | |
| 29125 | <1% | 308 | $936.53 | |
| 85379 | <1% | 1,335 | $933.47 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 70 | $914.06 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,262 | $898.92 |
| 76775 | <1% | 12 | $835.13 | |
| 86738 | <1% | 392 | $789.67 | |
| 84550 | <1% | 1,459 | $757.62 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 207 | $684.18 |
| 83615 | <1% | 1,259 | $660.83 | |
| 82803 | <1% | 16 | $648.41 | |
| 73552 | <1% | 73 | $645.48 | |
| 90715 | <1% | 607 | $642.44 | |
| 00300 | <1% | 14 | $594.69 | |
| 71250 | <1% | 15 | $569.64 | |
| 82610 | <1% | 358 | $567.59 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,039 | $539.50 |
| 82150 | <1% | 932 | $537.08 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,065 | $522.49 |
| 87581 | <1% | 162 | $518.86 | |
| 87088 | <1% | 1,629 | $515.30 | |
| 76857 | <1% | 27 | $511.52 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,303 | $505.87 |
| 73060 | <1% | 15 | $487.15 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 464 | $454.24 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 280 | $439.34 |
| 85384 | <1% | 1,045 | $425.71 | |
| 84156 | <1% | 1,646 | $379.36 | |
| 97116 | <1% | 132 | $373.65 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,803 | $360.98 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 26 | $302.76 |
| 92652 | <1% | 26 | $270.10 | |
| 85651 | <1% | 1,460 | $254.77 | |
| 82784 | <1% | 16 | $254.22 | |
| 76882 | <1% | 15 | $224.38 | |
| 96367 | <1% | 46 | $216.41 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 487 | $210.54 |
| 83002 | <1% | 15 | $200.22 | |
| 89051 | <1% | 49 | $197.63 | |
| 73564 | <1% | 14 | $176.02 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 107 | $159.01 |
| 73502 | <1% | 46 | $151.80 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 89 | $114.58 |
| 76641 | <1% | 13 | $108.61 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 59 | $83.01 |
| 87400 | <1% | 39 | $78.13 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 478 | $70.85 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 273 | $69.24 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 250 | $62.17 |
| 82043 | <1% | 173 | $58.15 | |
| 87420 | <1% | 21 | $57.19 | |
| 87109 | <1% | 13 | $48.63 | |
| 86308 | <1% | 61 | $25.88 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 544 | $25.00 |
| 85362 | <1% | 44 | $21.70 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 86 | $17.24 |
| 86592 | <1% | 52 | $15.35 | |
| 87430 | <1% | 53 | $15.06 | |
| 87081 | <1% | 46 | $15.03 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 29 | $10.65 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 15 | $8.68 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 51 | $8.52 |
| 99218 | <1% | 179 | $7.53 | |
| 87185 | <1% | 109 | $6.47 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 50 | $6.39 |
| 85660 | <1% | 26 | $6.09 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 50 | $4.30 |
| 00126 | <1% | 153 | $4.30 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 77 | $2.17 |
| 87425 | <1% | 12 | $2.17 | |
| 00920 | <1% | 691 | $1.95 | |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | 0% | 69 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 109 | $0.00 |
| 84145 | 0% | 31 | $0.00 | |
| 87806 | 0% | 21 | $0.00 | |
| 85007 | 0% | 79 | $0.00 | |
| J9260 | Injection, methotrexate sodium, 50 mg | 0% | 34 | $0.00 |
| 29515 | 0% | 12 | $0.00 | |
| 82010 | 0% | 13 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 15 | $0.00 |
| 51600 | 0% | 122 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 946 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 498 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 34 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 125 | $0.00 |
| 88300 | 0% | 16 | $0.00 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 133 | $0.00 |
| 88108 | 0% | 16 | $0.00 | |
| 88342 | 0% | 12 | $0.00 | |
| 88304 | 0% | 25 | $0.00 | |
| 00160 | 0% | 13 | $0.00 | |
| 86762 | 0% | 17 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 14 | $0.00 |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPAGANO, ANGELO (VP & AO)